default author photo

Prof Michael S. Hofman

Peter MacCallum Cancer Centre

305 Grattan Street

Parkville

Melbourne

Australia

SCHOLARLY PAPERS

3

DOWNLOADS

130

TOTAL CITATIONS

3

Scholarly Papers (3)

1.

Perioperative ctDNA as a Prognostic Biomarker in Endometrial Cancer - The CODEC Study

Number of pages: 25 Posted: 17 Jul 2025
Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Peter MacCallum Cancer Centre, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Royal Women's Hospital Melbourne - Oncology and Dysplasia Unit, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre and affiliation not provided to SSRN
Downloads 52 (1,041,696)

Abstract:

Loading...

Endometrial cancer, Biomarkers, ctDNA

2.

Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study

Number of pages: 21 Posted: 05 Mar 2021
University of California, Los Angeles (UCLA) - Ahmanson Translational Theranostics Division, University of California, Los Angeles (UCLA) - Ahmanson Translational Theranostics Division, University of California, Los Angeles (UCLA) - Department of Medicine Statistics Core, University of California, Los Angeles (UCLA) - Ahmanson Translational Theranostics Division, University Hospital Essen - Department of Urology, Technische Universität München (TUM) - Department of Nuclear Medicine, University of Duisburg-Essen - Department of Nuclear Medicine, Peter MacCallum Cancer Centre, University Hospital Heidelberg - Department of Nuclear Medicine, Excel Diagnostics and Nuclear Oncology Center, Technische Universität München (TUM) - Department of Urology, University Hospital Heidelberg - Department of Nuclear Medicine, University of California, Los Angeles (UCLA) - Ahmanson Translational Theranostics Division, Technische Universität München (TUM) - Department of Nuclear Medicine, University of California, Los Angeles (UCLA) - Ahmanson Translational Theranostics Division, Technische Universität München (TUM) - Department of Nuclear Medicine, UCLA Medical Center - Department of Urology, Excel Diagnostics and Nuclear Oncology Center, Heidelberg University - Department of Nuclear Medicine, University of California, Los Angeles (UCLA) - Department of Medicine Statistics Core, University of Duisburg-Essen - Department of Nuclear Medicine, University of California, Los Angeles (UCLA) - Department of Molecular and Medical Pharmacology (DMMP), Peter MacCallum Cancer Centre, University of Duisburg-Essen - Department of Nuclear Medicine and Technische Universität München (TUM) - Department of Nuclear Medicine
Downloads 43 (1,145,425)
Citation 3

Abstract:

Loading...

3.

Investigating the Difference in the Effects of [177lu] Lu-Psma-617 on Overall Survival between Therap and Vision Randomized Trials

Number of pages: 17 Posted: 04 Apr 2024
The University of Sydney, The University of Sydney, The University of Sydney, Peter MacCallum Cancer Centre, Royal North Shore Hospital, Monash University, The University of Sydney - NHMRC Clinical Trials Centre and University of Queensland
Downloads 35 (1,249,711)

Abstract:

Loading...

prostate cancer, Lutetium PSMA, Cabazitaxel, Survival, Treatment Crossover